These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 22881387)

  • 1. Effects of tuberculosis on the kinetics of CD4(+) T cell count among HIV-infected patients who initiated antiretroviral therapy early after tuberculosis treatment.
    Ku NS; Oh JO; Shin SY; Kim SB; Kim HW; Jeong SJ; Han SH; Song YG; Kim JM; Choi JY
    AIDS Res Hum Retroviruses; 2013 Feb; 29(2):226-30. PubMed ID: 22881387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of tuberculosis treatment on virologic and immunologic response to combination antiretroviral therapy among South African children.
    Soeters HM; Sawry S; Moultrie H; Rie AV
    J Acquir Immune Defic Syndr; 2014 Oct; 67(2):136-44. PubMed ID: 25072611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological recovery in tuberculosis/HIV co-infected patients on antiretroviral therapy: implication for tuberculosis preventive therapy.
    Karo B; Krause G; Castell S; Kollan C; Hamouda O; Haas W;
    BMC Infect Dis; 2017 Jul; 17(1):517. PubMed ID: 28743248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial.
    Amogne W; Aderaye G; Habtewold A; Yimer G; Makonnen E; Worku A; Sonnerborg A; Aklillu E; Lindquist L
    PLoS One; 2015; 10(5):e0122587. PubMed ID: 25966339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of tuberculosis treatment on virologic and CD4+ cell count response to combination antiretroviral therapy: a systematic review.
    Soeters HM; Napravnik S; Patel MR; Eron JJ; Van Rie A
    AIDS; 2014 Jan; 28(2):245-55. PubMed ID: 24072197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Markov model for the effects of virological failure on HIV/AIDS progression in tuberculosis co-infected patients receiving antiretroviral therapy in a rural clinic in northern South Africa.
    Shoko C; Chikobvu D; Bessong PO
    S Afr Med J; 2020 Mar; 110(4):313-319. PubMed ID: 32657744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T Cell Activation and Cytokine Profile of Tuberculosis and HIV-Positive Individuals during Antituberculous Treatment and Efavirenz-Based Regimens.
    da Silva TP; Giacoia-Gripp CB; Schmaltz CA; Sant Anna FM; Rolla V; Morgado MG
    PLoS One; 2013; 8(6):e66095. PubMed ID: 23840403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral therapy improves survival among TB-HIV co-infected patients who have CD4+ T-cell count above 350cells/mm
    Mutembo S; Mutanga JN; Musokotwane K; Alisheke L; Whalen CC
    BMC Infect Dis; 2016 Oct; 16(1):572. PubMed ID: 27751168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4⁺ T-cell counts of ≥ 350 cells/μL.
    Nanteza MW; Mayanja-Kizza H; Charlebois E; Srikantiah P; Lin R; Mupere E; Mugyenyi P; Boom WH; Mugerwa RD; Havlir DV; Whalen CC
    J Infect Dis; 2011 Sep; 204(6):884-92. PubMed ID: 21849285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition.
    Cingolani A; Cozzi Lepri A; Castagna A; Goletti D; De Luca A; Scarpellini P; Fanti I; Antinori A; d'Arminio Monforte A; Girardi E
    Clin Infect Dis; 2012 Mar; 54(6):853-61. PubMed ID: 22157323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of opportunistic infections after diagnosis of active tuberculosis in HIV-infected patients.
    Kwara A; Carter EJ; Rich JD; Flanigan TP
    AIDS Patient Care STDS; 2004 Jun; 18(6):341-7. PubMed ID: 15294084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of early antiretroviral therapy initiation to improve survival among HIV-infected adults with tuberculosis: a retrospective cohort study.
    Franke MF; Robins JM; Mugabo J; Kaigamba F; Cain LE; Fleming JG; Murray MB
    PLoS Med; 2011 May; 8(5):e1001029. PubMed ID: 21559327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid suppression of HIV-RNA is associated with improved control of immune activation in Mozambican adults initiating antiretroviral therapy with low CD4 counts.
    Almeida JM; Letang E; Nhampossa T; Ayala E; David C; Menendez C; Gascon J; Alonso P; Naniche D
    AIDS Res Hum Retroviruses; 2011 Jul; 27(7):705-11. PubMed ID: 21091388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study.
    Manosuthi W; Mankatitham W; Lueangniyomkul A; Thongyen S; Likanonsakul S; Suwanvattana P; Thawornwan U; Suntisuklappon B; Nilkamhang S; Sungkanuparph S;
    J Acquir Immune Defic Syndr; 2012 Aug; 60(4):377-83. PubMed ID: 22592586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delay in cART initiation results in persistent immune dysregulation and poor recovery of T-cell phenotype despite a decade of successful HIV suppression.
    Ndumbi P; Falutz J; Pant Pai N; Tsoukas CM
    PLoS One; 2014; 9(4):e94018. PubMed ID: 24710051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients.
    Bouteloup V; Sabin C; Mocroft A; Gras L; Pantazis N; Le Moing V; d'Arminio Monforte A; Mary-Krause M; Roca B; Miro JM; Battegay M; Brockmeyer N; Berenguer J; Morlat P; Obel N; De Wit S; Fätkenheuer G; Zangerle R; Ghosn J; Pérez-Hoyos S; Campbell M; Prins M; Chêne G; Meyer L; Dorrucci M; Torti C; Thiébaut R;
    HIV Med; 2017 Jan; 18(1):33-44. PubMed ID: 27625009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
    Swaminathan S; Padmapriyadarsini C; Venkatesan P; Narendran G; Ramesh Kumar S; Iliayas S; Menon PA; Selvaraju S; Pooranagangadevi NP; Bhavani PK; Ponnuraja C; Dilip M; Ramachandran R
    Clin Infect Dis; 2011 Oct; 53(7):716-24. PubMed ID: 21890776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.
    Dean GL; Edwards SG; Ives NJ; Matthews G; Fox EF; Navaratne L; Fisher M; Taylor GP; Miller R; Taylor CB; de Ruiter A; Pozniak AL
    AIDS; 2002 Jan; 16(1):75-83. PubMed ID: 11741165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuberculosis treatment in HIV infected Ugandans with CD4 counts>350 cells/mm reduces immune activation with no effect on HIV load or CD4 count.
    Mahan CS; Walusimbi M; Johnson DF; Lancioni C; Charlebois E; Baseke J; Chervenak KA; Mugerwa RD; Havlir DV; Mayanja-Kizza H; Whalen CC; Boom WH;
    PLoS One; 2010 Feb; 5(2):e9138. PubMed ID: 20179751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of the interval between the initiation of antiretroviral therapy and the initiation of anti-tuberculosis treatment in HIV/tuberculosis-coinfected patients: results from the TREAT Asia HIV Observational Database.
    Han SH; Zhou J; Lee MP; Zhao H; Chen YM; Kumarasamy N; Pujari S; Lee C; Omar SF; Ditangco R; Phanuphak N; Kiertiburanakul S; Chaiwarith R; Merati TP; Yunihastuti E; Tanuma J; Saphonn V; Sohn AH; Choi JY;
    HIV Med; 2014 Feb; 15(2):77-85. PubMed ID: 23980589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.